Cite
HARVARD Citation
Del Prato, S. et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 398 (10313), pp. 1811-1824. [Online].